Endo/Vernalis Seek Menstrual Migraine Indication For Frova
This article was originally published in The Pink Sheet Daily
Executive Summary
sNDA will be filed with FDA in the coming weeks following positive Phase III trial results.
You may also be interested in...
Frova Menstrual Migraine Claim Gets Extension
New action date is Sept. 30 for the supplemental indication for frovatriptan, Endo/Vernalis announce.
Frova Menstrual Migraine Claim Gets Extension
New action date is Sept. 30 for the supplemental indication for frovatriptan, Endo/Vernalis announce.
Endo, Vernalis Seek First Triptan Menstrual Migraine Indication With Frova sNDA
Frovatriptan sNDA is supported by data from four studies, including two Phase III trials evaluating efficacy in short-term prevention of MM.